Rebecca L Emery1, Melissa P Gregory2, Jennifer L Grace3, Michele D Levine3. 1. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. Electronic address: rle21@pitt.edu. 2. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, USA; University of Pittsburgh, Graduate School of Public Health, 130 De Soto Street, Pittsburgh, PA 15261, USA. 3. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA 15213, USA.
Abstract
BACKGROUND: Following tobacco and alcohol, cannabis is the most commonly used substance during pregnancy. Given the high prevalence of concurrent cannabis and tobacco use as well as the health consequences associated with prenatal substance use, we sought to document the relative contributions of psychosocial and psychiatric factors commonly associated with cannabis use in predicting a lifetime cannabis use disorder (CUD) among women who had quit smoking tobacco as a result of pregnancy. METHODS:Pregnant former tobacco smokers (n=273) enrolled in a larger randomized controlled trial for postpartum tobacco relapse prevention completed semi-structured psychiatric interviews and self-reported demographic, pregnancy, health, psychosocial, and tobacco use factors during their third trimester of pregnancy. RESULTS: In total, 14% (n=38) of women met criteria for a lifetime CUD. The strongest predictors of a lifetime CUD were a history of having multiple psychiatric disorders (OR=36.44; 95% CI=5.03-264.27; p<0.001) followed by a lifetime alcohol use disorder (OR=3.54; 95% CI=1.27-9.87; p<0.05). In addition, more frequent attempts to quit smoking tobacco (OR=1.12; 95% CI=1.01-1.25; p<0.05) and lower self-efficacy about weight management after quitting smoking tobacco (OR=0.78; 95% CI=0.62-0.97; p<0.05) also were significantly associated with a lifetime CUD. CONCLUSIONS:Women with a history of both cannabis and tobacco dependence may represent a subset of women who need more specialized treatment during the perinatal period to improve substance use outcomes.
RCT Entities:
BACKGROUND: Following tobacco and alcohol, cannabis is the most commonly used substance during pregnancy. Given the high prevalence of concurrent cannabis and tobacco use as well as the health consequences associated with prenatal substance use, we sought to document the relative contributions of psychosocial and psychiatric factors commonly associated with cannabis use in predicting a lifetime cannabis use disorder (CUD) among women who had quit smoking tobacco as a result of pregnancy. METHODS: Pregnant former tobacco smokers (n=273) enrolled in a larger randomized controlled trial for postpartum tobacco relapse prevention completed semi-structured psychiatric interviews and self-reported demographic, pregnancy, health, psychosocial, and tobacco use factors during their third trimester of pregnancy. RESULTS: In total, 14% (n=38) of women met criteria for a lifetime CUD. The strongest predictors of a lifetime CUD were a history of having multiple psychiatric disorders (OR=36.44; 95% CI=5.03-264.27; p<0.001) followed by a lifetime alcohol use disorder (OR=3.54; 95% CI=1.27-9.87; p<0.05). In addition, more frequent attempts to quit smoking tobacco (OR=1.12; 95% CI=1.01-1.25; p<0.05) and lower self-efficacy about weight management after quitting smoking tobacco (OR=0.78; 95% CI=0.62-0.97; p<0.05) also were significantly associated with a lifetime CUD. CONCLUSIONS:Women with a history of both cannabis and tobacco dependence may represent a subset of women who need more specialized treatment during the perinatal period to improve substance use outcomes.
Authors: Matthew M Clark; Richard D Hurt; Ivana T Croghan; Christi A Patten; Paul Novotny; Jeff A Sloan; Shaker R Dakhil; Gary A Croghan; Edward J Wos; Kendrith M Rowland; Albert Bernath; Roscoe F Morton; Sachdex P Thomas; Loren K Tschetter; Stewart Garneau; Philip J Stella; Larry P Ebbert; Donald B Wender; Charles L Loprinzi Journal: Addict Behav Date: 2005-08-30 Impact factor: 3.913
Authors: David S Timberlake; Brett C Haberstick; Christian J Hopfer; Josh Bricker; Joseph T Sakai; Jeffrey M Lessem; John K Hewitt Journal: Drug Alcohol Depend Date: 2006-12-14 Impact factor: 4.492
Authors: Hanan El Marroun; Henning Tiemeier; Vincent W V Jaddoe; Albert Hofman; Johan P Mackenbach; Eric A P Steegers; Frank C Verhulst; Wim van den Brink; Anja C Huizink Journal: Drug Alcohol Depend Date: 2008-07-07 Impact factor: 4.492
Authors: Lissa Dutra; Georgia Stathopoulou; Shawnee L Basden; Teresa M Leyro; Mark B Powers; Michael W Otto Journal: Am J Psychiatry Date: 2008-01-15 Impact factor: 18.112
Authors: Laura R Stroud; George D Papandonatos; Meaghan McCallum; Tessa Kehoe; Amy L Salisbury; Marilyn A Huestis Journal: Neurotoxicol Teratol Date: 2018-09-26 Impact factor: 3.763
Authors: Laura R Stroud; George D Papandonatos; Nancy C Jao; Chrystal Vergara-Lopez; Marilyn A Huestis; Amy L Salisbury Journal: Neurotoxicol Teratol Date: 2020-04-11 Impact factor: 3.763